about
Cancer as a metabolic diseaseCancer cachexiaIKK2 inhibitor alleviates kidney and wasting diseases in a murine model of human AIDSThalidomide in the treatment of cancer cachexia: a randomised placebo controlled trialThalidomide and cancer cachexia: old problem, new hope?A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), resistance training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients--ACCeRT study.The effect of neoadjuvant chemoradiotherapy on whole-body physical fitness and skeletal muscle mitochondrial oxidative phosphorylation in vivo in locally advanced rectal cancer patients--an observational pilot studyA difficult clinical problem: diagnosis, impact and clinical management of cachexia in palliative care.Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients.Role of omega-3 fatty acid supplementation in inflammation and malignancy.Cancer Appetite and Symptom Questionnaire (CASQ) for Brazilian Patients: Cross-Cultural Adaptation and Validation StudyReview article: anorexia and cachexia in gastrointestinal cancer.Emerging role for regulated in development and DNA damage 1 (REDD1) in the regulation of skeletal muscle metabolism.Dietary restriction reduces angiogenesis and growth in an orthotopic mouse brain tumour model.Review and follow-up of patients using a regional sperm cryopreservation service: ensuring that resources are targeted to those patients most in need.The embedded tumour: host physiology is important for the evaluation of tumour growth.Changes in diet associated with cancer: An evolutionary perspective.Sydnone 1: A Mesoionic Compound with Antitumoral and Haematological Effects In Vivo.Understanding tumor anabolism and patient catabolism in cancer-associated cachexiaSimilar changes of hypothalamic feeding-regulating peptides mRNAs and plasma leptin levels in PTHrP-, LIF-secreting tumors-induced cachectic rats and adjuvant arthritic rats.Effects of conjugated linoleic acid on myogenic and inflammatory responses in a human primary muscle and tumor coculture model.Body-weight change and physical functioning among young old adults.Molecular analysis of lipid-depleting factor in a colon-26-inoculated cancer cachexia model.Associations between oral complications and days to death in palliative care patients.Cancer cachexia-when proteasomal inhibition is not enough.Biochemical nutritional profile of liver cirrhosis patients with hepatocellular carcinoma.Role of NF-kappaB and cytokine in experimental cancer cachexia.Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: Effects on survival, metabolism, and function.Understanding cachexia and excessive weight loss in cancer.Anorexia and weight loss in long-term survivors of haematological malignancies.Hyposmia: an underestimated and frequent adverse effect of chemotherapy.Preoperative glucose and protein metabolism: the influence of diabetes mellitus type 2 in patients with colorectal tumors.Long-term follow-up of the potential benefits of early nutritional intervention in adults with upper gastrointestinal cancer: a pilot randomised trial.Testicular cancer patients undergoing cisplatin based chemotherapy exhibit temporary olfactory threshold scores changes.Levofloxacin effect on erlotinib absorption. Evaluation of the interaction in undernutrition situations through population pharmacokinetic analysis in rats.l-Glutamine supplementation promotes an improved energetic balance in Walker-256 tumor-bearing rats.Impact of nutritional status on the pharmacokinetics of erlotinib in rats.
P2860
Q21245061-8301AC20-A71C-4B40-8D2D-27247A22C173Q21245747-64B6005C-426E-41B5-B4FF-1BBF60F2131BQ24672467-5B462639-623C-42CF-9973-C6D4CE0BC9AAQ24685678-5BBCC048-2160-4CEB-ABA1-6A7CA5C854C4Q33985598-6E9E36D1-EF1B-4956-89EB-1A32CE708448Q34082057-D0AC779B-7EF6-4725-A05F-9FE5C5E4FBBEQ34639381-20FA88B0-6661-4D1A-9AFE-8C6E509E52CEQ34995229-59114851-9A51-4F05-8D9D-B5A9484094B7Q35225534-AD4FA001-93E4-45CC-A8F6-686F566A8C0DQ35785440-F4B47BD4-7D32-41A2-90A7-FF2250E5F510Q36044947-AB2DE1FC-AB36-4B9F-A223-022FF19C39BFQ36266402-211B45B6-601A-4F68-BDEF-BCB2A4F04747Q37139408-FA984849-E9E7-4E8E-AABE-8776314D79F3Q37352779-6BA1FD02-25A6-40BA-9346-485055F48D60Q38530560-110733F7-33BF-4A36-BF79-A4C651988B5BQ38611320-81EF55C1-409C-4571-9BFF-E98A2A9A1C4BQ38674691-AB10C6BF-8E50-41DE-85BC-9C8F0CF528AEQ38808624-37D6EBB9-AAB3-41EF-B526-5A203D81DFACQ39339489-F560546C-899D-4916-BAAE-223FFF5F7361Q39684347-E003843B-D509-4764-9C00-A33D1778E67AQ39786064-A91E5308-85EB-4D95-BFA4-D26E31EA610DQ40523855-25376939-D9BF-46A2-98FC-D06F75794710Q40706993-8C772F8B-9957-47EC-AA96-1CC515FF1FE4Q40952000-DC909B75-9CF3-4582-97DA-009E5E2FBBAFQ41852980-E4FACB28-ACA8-4359-90DB-811BD84547E0Q42222681-24130BE8-4DD0-4311-83C2-3F0293C5EEF6Q43206632-41C82462-6B16-408E-8EE5-8CA328A80EA4Q45102906-E70E5DBE-09CD-4952-9194-B864BE5B1E60Q47360517-26D01951-A4DC-4B63-97AB-52A8095A4355Q47436380-016CBD9E-A6EB-4714-8AD5-524AE6490AAFQ48047195-1E331EFE-3595-4FE6-8C91-BB47FC07DD23Q48248546-F662C80F-452C-4BD4-B3B6-B21A8D067D30Q48282078-387DAB6A-088D-466B-BA09-7BC61537BC7DQ50712169-9E4C2F57-4FA5-46DC-85A2-216EF6DAD63CQ50947265-8AD15851-F0DF-4F49-9E62-070618874814Q51084307-94C1A068-7721-41C1-82FA-97BC166B7C6FQ54284937-DF9A2160-C219-41B2-B2D5-2044CDAE4739
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
Cancer anorexia and cachexia.
@ast
Cancer anorexia and cachexia.
@en
type
label
Cancer anorexia and cachexia.
@ast
Cancer anorexia and cachexia.
@en
prefLabel
Cancer anorexia and cachexia.
@ast
Cancer anorexia and cachexia.
@en
P1433
P1476
Cancer anorexia and cachexia.
@en
P2093
Tisdale MJ
P304
P356
10.1016/S0899-9007(01)00506-8
P577
2001-05-01T00:00:00Z